Alpharadin og prostatakreft med spredning til skjelett
Alpharadin and prostate cancer with skeletal metastases
The nature of sclerotic/osteoblastic bone metastases and the microdistribution of primitive bone matrix; i.e. the target for Radium-223 (Alpharadin), is a prerequisite for the therapeutic effect.
Click here to view three slides visualizing this dimension.
A direct link to the ongoing phase III trial, that recently was activated in US centers, directs you to the NIH/NCI clinical trials web page - click here.
Review of the clinical development of Radium 223 - Alpharadin.
Chapter 10 in a recent textbook on targeted radionuclide tumour therapy by Springer Verlag, 2008.
Click here to open the chapter in PDF format.
This presentation, made by Algeta ASA (see www.algeta.com), presents important aspects on the efficacy and safety of Alpharadin.
Also it provides an introduction to put this novel bone-seeking targeted therapy based on alpha-paticle emitting Radium-223 in a comparative context; i.e. to the two other radiopharmaceuticels approved to releive pain and to the cytostatic drug Taxotere.
Click here for a pdf of the presentation